沛嘉医疗-B(09996)：2024年全年收入约6.1亿元-6.3亿元同比增长约38.3%-42.8%

智通财经

Feb 10, 2025

智通财经APP讯，沛嘉医疗-B(09996)发布截至2024年12月31日止年度营运数据，收入约人民币6.1亿元-6.3亿元，同比增长约38.3%-42.8%。

强劲的收入增长主要归功于：(i)集团所有神经介入产品线的持续快速增长;及(ii)集团在中国经导管主动脉瓣置换(TAVR)市场的份额扩大。

于报告期间，由于手术渗透率的提高、集团在带量采购中中标，以及其全面的产品管线及有效的营销策略，出血类、缺血类及通路类神经介入产品线均实现显著的收入增长。主要驱动因素包括：

(i)DCwire^®微导丝在全国范围内的首年成功推出，得到了用户的积极反馈和市场的广泛采用;

(ii)集团的现有优势产品Syphonet^®取栓支架及Fastunnel^®输送型球囊扩张导管凭借差异化产品设计及创新手术技术进一步渗透市场;及

(iii)凭借可靠的产品质量及品牌知名度，集团的弹簧圈产品在带量采购中获持续采用。

于报告期间，集团继续致力于市场教育及开发，不断扩大其第一代及第二代TAVR产品(即TaurusOne^®及TaurusElite^®)的市场份额。于报告期间，TaurusOne^®及TaurusElite^®在150多间新医院中获得采用，全年合计植入超过3400台。截至2024年12月31日，集团的TAVR产品已累计覆盖近650间医院。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2510839465"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2510839465\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2510839465?lang=en_US&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2025-02-10 17:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2510839465","market":"sh","top_or_hot":-1,"title":"沛嘉医疗-B(09996)：2024年全年收入约6.1亿元-6.3亿元 同比增长约38.3%-42.8%","media":"智通财经","content":"<html><body><p>智通财经APP讯，<a href=\"https://laohu8.com/S/09996\">沛嘉医疗-B</a>(09996)发布截至2024年12月31日止年度营运数据，收入约人民币6.1亿元-6.3亿元，同比增长约38.3%-42.8%。</p><p>强劲的收入增长主要归功于：(i)集团所有神经介入产品线的持续快速增长;及(ii)集团在中国经导管主动脉瓣置换(TAVR)市场的份额扩大。</p><p>于报告期间，由于手术渗透率的提高、集团在带量采购中中标，以及其全面的产品管线及有效的营销策略，出血类、缺血类及通路类神经介入产品线均实现显著的收入增长。主要驱动因素包括：</p><p>(i)DCwire<sup>®</sup>微导丝在全国范围内的首年成功推出，得到了用户的积极反馈和市场的广泛采用;</p><p>(ii)集团的现有优势产品Syphonet<sup>®</sup>取栓支架及Fastunnel<sup>®</sup>输送型球囊扩张导管凭借差异化产品设计及创新手术技术进一步渗透市场;及</p><p>(iii)凭借可靠的产品质量及品牌知名度，集团的弹簧圈产品在带量采购中获持续采用。</p><p>于报告期间，集团继续致力于市场教育及开发，不断扩大其第一代及第二代TAVR产品(即TaurusOne<sup>®</sup>及TaurusElite<sup>®</sup>)的市场份额。于报告期间，TaurusOne<sup>®</sup>及TaurusElite<sup>®</sup>在150多间新医院中获得采用，全年合计植入超过3400台。截至2024年12月31日，集团的TAVR产品已累计覆盖近650间医院。</p></body></html>","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>沛嘉医疗-B(09996)：2024年全年收入约6.1亿元-6.3亿元 同比增长约38.3%-42.8%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n沛嘉医疗-B(09996)：2024年全年收入约6.1亿元-6.3亿元 同比增长约38.3%-42.8%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-02-10 17:28 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1247841.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，沛嘉医疗-B(09996)发布截至2024年12月31日止年度营运数据，收入约人民币6.1亿元-6.3亿元，同比增长约38.3%-42.8%。强劲的收入增长主要归功于：(i)集团所有神经介入产品线的持续快速增长;及(ii)集团在中国经导管主动脉瓣置换(TAVR)市场的份额扩大。于报告期间，由于手术渗透率的提高、集团在带量采购中中标，以及其全面的产品管线及有效的营销策略，出血类、...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1247841.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1574","symbol_name":"生物医药B类股","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1247841.html","article_id":"2510839465","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2510839465","pubTimestamp":1739179692,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP讯，沛嘉医疗-B 发布截至2024年12月31日止年度营运数据，收入约人民币6.1亿元-6.3亿元，同比增长约38.3%-42.8%。于报告期间，集团继续致力于市场教育及开发，不断扩大其第一代及第二代TAVR产品的市场份额。于报告期间，TaurusOne及TaurusElite在150多间新医院中获得采用，全年合计植入超过3400台。截至2024年12月31日，集团的TAVR产品已累计覆盖近650间医院。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"159891":"医疗","BK1574":"生物医药B类股","09996":"沛嘉医疗-B","BK1583":"高瓴概念","BK1100":"医疗保健设备"},"translate_title":"Peijia Medical-B (09996): The annual revenue in 2024 will be approximately 610 million to 630 million yuan, a year-on-year increase of approximately 38.3% to 42.8%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159891":1,"09996":1},"content_text":"智通财经APP讯，沛嘉医疗-B(09996)发布截至2024年12月31日止年度营运数据，收入约人民币6.1亿元-6.3亿元，同比增长约38.3%-42.8%。强劲的收入增长主要归功于：(i)集团所有神经介入产品线的持续快速增长;及(ii)集团在中国经导管主动脉瓣置换(TAVR)市场的份额扩大。于报告期间，由于手术渗透率的提高、集团在带量采购中中标，以及其全面的产品管线及有效的营销策略，出血类、缺血类及通路类神经介入产品线均实现显著的收入增长。主要驱动因素包括：(i)DCwire®微导丝在全国范围内的首年成功推出，得到了用户的积极反馈和市场的广泛采用;(ii)集团的现有优势产品Syphonet®取栓支架及Fastunnel®输送型球囊扩张导管凭借差异化产品设计及创新手术技术进一步渗透市场;及(iii)凭借可靠的产品质量及品牌知名度，集团的弹簧圈产品在带量采购中获持续采用。于报告期间，集团继续致力于市场教育及开发，不断扩大其第一代及第二代TAVR产品(即TaurusOne®及TaurusElite®)的市场份额。于报告期间，TaurusOne®及TaurusElite®在150多间新医院中获得采用，全年合计植入超过3400台。截至2024年12月31日，集团的TAVR产品已累计覆盖近650间医院。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}